KRAS and neoplasm: Previously, we reported that treatment of a K-ras-driven skin cancer mouse model with either the pan-Pak inhibitor PF3758309 or the group I-specific Pak inhibitor Frax597 induced near complete suppression of Pak activity in tumor tissues and had a strong repressive effect on tumor initiation and progression [11].